Jumpstart has been asked to bring its unrivalled expertise to the important BioInfect 2014 conference, an event which examines critical issues around anti-infectives and resistance.
The company will exhibit at the major one-day conference at the Alderley Park Conference Centre in Cheshire on November 4 as part of its involvement with some of the most exciting life science companies in Britain.
Its involvement follows its decision last month (September) to join forces with Bionow, the body which supports business growth, competitiveness and innovation within the biomedical and life science sectors across Northern England.
At the BioInfect event, Simon Fisk and David Milnes, both business analysts at Jumpstart and members of Bionow, will be explaining to visitors why, even though biomedical and life-sciences companies have already been extremely successful with R&D tax relief claims, the sector is still failing to secure a potential financial windfall from the millions that go unclaimed each year.
Jumpstart managing director Brian Williamson has already taken part last month in a panel discussion at the BioCap conference in Manchester - an event which brings together international investors and companies who are seeking finance - on alternative sources of funding for innovative companies.
Jumpstart's membership of Bionow is significantly beneficial to both parties. The company has helped clients recover more than £43 million from HMRC and is providing information to Bionow which is relevant to life science businesses in the area of R&D tax relief.
Bionow's membership services add value and cost-efficiency to scientific, clinical and business operations within early stage and growth-oriented firms. Its membership base includes start-ups and early stage firms as well as established growth-oriented companies.
Simon Fisk said: "BioInfect 2014 is setting the global anti-microbial agenda and will feature discussions on the national and international aspects of progress and incentives via supportive regulation."
Brian Williamson said: "Our involvement with some of the most exciting life science companies in Britain will help us to understand how we can best help the sector to achieve important new funding streams."